RE:RE:Fairness opinion I'm sure BB made assumptions about cash flows beyond 2026 to do a DCF analysis but what the hell did they assume about clinical trial outcomes, new product launches, joint ventures, etc. They probably valued CZO on existing base business only.
"I thought DCF models were for 10 years with a terminal value assigned as well, but they stopped at 2026?"